Analysts at H.C. Wainwright have maintained a Buy rating on Alto Neuroscience, citing confidence in the company’s strategic direction and future prospects. Furthermore, Alto Neuroscience presented ...

Alto Ingredients CEO Bryon McGregor said the new board members’ experience "will be invaluable as Alto Ingredients continues to expand our market presence." The company describes itself as a producer ...

MOUNTAIN VIEW, Calif. - Alto Neuroscience, Inc. (NYSE:ANRO), a clinical-stage biopharmaceutical company with a market capitalization of $68 million, has identified a patient selection biomarker in its ...

Analysts at H.C. Wainwright have maintained a Buy rating on Alto Neuroscience, citing confidence in the company’s strategic direction and future prospects. Furthermore, Alto Neuroscience presented ...

In addition, Alto has acquired CTC-413, now ALTO-208, aimed at treating Parkinson’s disease, with an upfront payment of $1.75 million and potential milestone payments up to $71.5 million. H.C.

Analysts at H.C. Wainwright have maintained a Buy rating on Alto Neuroscience, citing confidence in the company’s strategic direction and future prospects.

Alto Neuroscience’s phase 2 depression trial has missed its primary efficacy endpoint, as patients on the drug candidate fared no better on a measure of alertness and mood than their peers on ...

H.C. Wainwright has maintained its Buy rating on Alto Neuroscience, setting a price target of $10, reflecting confidence in the company’s strategic direction and potential impact of ALTO-207.